Page 69 - Sohini Das

India's Serum Institute to make Novavax's Covid vaccine for US market

The company has indicated in the first quarter earnings call that it has reached a major milestone in its pathway to an emergency use authorisation from the US Food and Drugs Administration

Mumbai boosts hospital capacity as Covid cases rise, bed occupancy doubles

Around 10 out of every 1,000 beds are already occupied by Covid-19 patients, up from 4 a week ago

Covid-19 pandemic: Maharashtra, Kerala on high alert as cases spike

On Tuesday, Maharashtra recorded 1,881 new Covid cases, 81 per cent more than the previous day and highest since February 18

Paraguay cancels orders for one million doses of Covaxin, say sources

Media reports cite quality issues; sources say Bharat Biotech had stopped production and exports in April, any pending orders stand cancelled

Price is the key growth driver of Indian pharma market, shows AWACS data

Market set to grow by 2.5-5% in calendar 2022. could even hit 5% due to a strong seasonal sales such as anti-infectives, and impact of NLEM drugs price hike

Boehringer Ingelheim obtains ad-interim injunctions on 4 Indian pharma cos

The firms had launched generic versions of Boehringer's patent-protected drug Linagliptin, which is marketed under the brand name Trajenta

Shot in the arm for boosters: Demand jumps 20% as Covid cases spike

On Saturday, the daily vaccination in the state touched 100,000, said Sachin Desai, state immunisation officer

Covid-19 vaccine: SII to test Novavax for Omicron variant strain

The Pune-based company has also got a nod from the Indian drug regulator's office to manufacture trial batches of this vaccine for the purpose of testing, sources indicated.

Biological E's Corbevax gets DCGI nod as a heterologous Covid booster dose

The Hyderabad-based company claimed that the booster dose of Corbevax increased the neutralising antibody titers in the Covishield and Covaxin groups significantly when compared to placebo

Covid-19 cases at three-month high; up vigil, says health ministry

Centre writes to Maharashtra, Karnataka, Kerala, Telangana & TN

WhatsApp India, GoI join hands to leverage Chatbot for non-Covid use-cases

These collaborations happen despite several run ins between the two on regulatory issues

India mulls study on long-term impact of Covid-19 vaccines on children

Children have not reported very serious disease cases, apart from those who had serious co-morbidities like cancer, other underlying ailments

Maharashtra CM warns of curbs as Covid case positivity spikes in Mumbai

Meanwhile, the Mumbai civic body has also asked the jumbo Covid centres to be fully staffed and be on a standby

Renew focus on communicable diseases, not Covid-19 pandemic: Experts

Public health expert Anish T S says during the pandemic, reported cases of tuberculosis and typhoid were fewer

Covid being endemic is as mystical and mythical as herd immunity: N K Arora

'Vaccine equity not possible if we include imported mRNA vaccines in our programme', said Arora

Covid endemic, we've to plan how we live with it, says Gagandeep Kang

'Whether we are in the endemic stage depends on how we define endemicity. Covid-19 disease is in the population and would be in the population for a very long time', said Kang

Specialty business set to spur growth for Sun Pharma in next 3 yrs: Experts

Global specialty drug sales for Sun Pharma have grown by 39% YoY in FY22 to $674 million

From DRL to Glenmark, pharma companies see steady revenue growth in Russia

Strong sales in Q4 during war aided by 'stocking up of inventory'

Sun Pharma posts Rs 2,277 cr Q4 loss over settlement of pending US lawsuits

Provides for the settlement charges, says adjusted profit for Q4FY22 at Rs 1582 cr, up 18% YoY after excluding exceptional items of Rs 3,935.7 cr and one-time tax gain of Rs 76.4 cr

Jubilant to double injectable capacity in US at a cost of $193 mn

Signs agreement with US biomedical dept